L & S Advisors’s AstraZeneca AZN Stock Holding History

L & S Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.66M	Sell	23,613 -18,733	-44%	-$3.61M	0.59%	54
2025 Q4	$7.79M	Buy	+42,346	New	+$7.43M	0.72%	35
2016 Q4	–	Sell	-49,814	Closed	-$3.27M	–	165
2016 Q3	$3.27M	Buy	+49,814	New	+$3.26M	0.9%	43
2015 Q1	–	Sell	-19,742	Closed	-$1.39M	–	89
2014 Q4	$1.39M	Buy	19,742 +14,379	+268%	+$1.03M	0.43%	57
2014 Q3	$383K	Sell	5,363 -31,159	-85%	-$2.28M	0.19%	45
2014 Q2	$2.71M	Buy	36,522 +27,970	+327%	+$2.02M	1.08%	33
2014 Q1	$555K	Buy	+8,552	New	+$552K	0.3%	52

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

L & S Advisors's AZN Position: Q1 2026 in Review

L & S Advisors reduced its AstraZeneca (AZN) stake by 44% in Q1 2026, selling an estimated $3.61M and leaving 23,613 shares worth $4.66M. The position accounts for 0.59% of the portfolio, ranked #54.

L & S Advisors first reported a position in AZN in Q1 2014 and has held it in 7 quarters since. The position peaked at $7.79M in Q4 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

L & S Advisors held 23,613 shares of AstraZeneca worth $4.66M as of Q1 2026.
L & S Advisors sold 18,733 AstraZeneca shares in Q1 2026, an estimated $3.61M.
AstraZeneca made up 0.59% of L & S Advisors's portfolio in Q1 2026, its #54 holding.
L & S Advisors first reported a position in AstraZeneca in Q1 2014 and has held it in 7 quarters since.
L & S Advisors's AstraZeneca position peaked at $7.79M in Q4 2025.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on L & S Advisors's 13F filing for Q1 2026, filed 11 May 2026.